益生股份(002458) - 2019 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2019 reached ¥651,486,939.01, representing a 193.55% increase compared to ¥221,934,934.18 in the same period last year[7] - Net profit attributable to shareholders was ¥381,941,911.73, a significant increase of 3,503.70% from ¥10,598,605.80 in the previous year[7] - Basic earnings per share increased to ¥0.67, up 3,250.00% from ¥0.02 in the previous year[7] - Operating revenue for Q1 2019 was ¥651,486,939.01, a 193.55% increase year-over-year, driven by substantial price hikes of main products[14] - Net profit for Q1 2019 reached ¥381,276,197.99, reflecting a remarkable increase of 3,708.62% compared to the same period last year, mainly due to increased product prices[16] - Operating profit for Q1 2019 was CNY 381,323,085.06, compared to CNY 6,837,185.48 in Q1 2018, indicating a substantial improvement in profitability[42] - The total profit for Q1 2019 was CNY 381,276,197.99, compared to CNY 10,010,873.21 in Q1 2018, marking a significant increase[42] Cash Flow - The net cash flow from operating activities was ¥301,278,074.55, showing a remarkable improvement of 938.69% compared to -¥35,922,308.07 in the same period last year[7] - Cash received from sales and services in Q1 2019 was ¥642,407,239.63, an increase of 206.81% year-over-year, resulting from higher sales revenue[16] - The company reported cash inflows from operating activities totaling ¥644,988,350.66, compared to ¥210,724,461.37 in the previous period, marking an increase of about 205.5%[50] - The net cash flow from operating activities was ¥191,880,063.29, a significant improvement from the previous period's net cash flow of -¥68,174,433.30[53] - Cash inflow from operating activities totaled ¥693,396,777.26, compared to ¥245,470,918.63 in the prior period, indicating a growth of approximately 182%[53] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,563,047,179.00, a 10.92% increase from ¥2,310,623,565.50 at the end of the previous year[7] - Total liabilities decreased to ¥641,371,318.83 from ¥705,763,426.12, indicating a reduction of approximately 9.1%[30] - Current assets increased to ¥717,517,267.64 as of March 31, 2019, up from ¥481,446,226.06 on December 31, 2018, representing a growth of approximately 49.0%[26] - Total non-current assets amounted to ¥1,845,529,911.36, slightly up from ¥1,829,177,339.44, showing a growth of approximately 0.9%[28] - Total equity increased to CNY 1,757,173,685.93 from CNY 1,517,892,406.95, representing a growth of approximately 15.7%[40] Shareholder Information - The top shareholder, Cao Jisheng, holds 41.89% of the shares, with a total of 141,338,384 shares[9] - The company did not engage in any repurchase transactions during the reporting period[11] Research and Development - Research and development expenses for Q1 2019 amounted to ¥4,396,236.04, up 146.23% year-over-year, due to increased investments in disease purification and biosecurity systems[14] - Research and development expenses for Q1 2019 were CNY 4,396,236.04, up from CNY 1,785,384.65 in the previous year, indicating a focus on innovation and development[40] Financial Expenses and Income - Financial expenses decreased by 43.92% to ¥3,730,140.85 in Q1 2019, due to reduced bank loan balances and increased interest income[14] - The company reported an investment income of ¥11,699,759.54 for Q1 2019, a 273.16% increase year-over-year, primarily from profits of an associated company[14] - The company reported investment income of CNY 11,699,759.54, a recovery from a loss of CNY 6,756,622.78 in the same period last year[40] Other Financial Metrics - The weighted average return on equity was 21.37%, a significant increase from 0.87% in the previous year[7] - The company's gross profit margin improved significantly, contributing to a 213.72% increase in retained earnings to ¥461,608,334.55 as of March 31, 2019[14]